drugset / Trial / NCT07486089
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Non-randomizedSequentialOpen-labelTreatment
Summary
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.
Timeline
- Start
- 2026-02-02
- Primary completion
- 2027-02-14
- Completion
- 2028-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dual-target CAR-NK cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |